Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis

Patients with moderate to severe allergic rhinitis may benefit from subcutaneous immunotherapy (SCIT), despite the risk of systemic allergic reaction. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for interleukin‐4 and interleukin‐13, key drivers of the typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamal, Mohamed A., Franchetti, Yoko, Lai, Ching‐Ha, Xu, Christine, Wang, Claire Q., Radin, Allen R., O'Brien, Meagan P., Ruddy, Marcella, Davis, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303412/
https://www.ncbi.nlm.nih.gov/pubmed/34791679
http://dx.doi.org/10.1002/jcph.2004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303412/
https://www.ncbi.nlm.nih.gov/pubmed/34791679
http://dx.doi.org/10.1002/jcph.2004

Ejemplares similares